Yes, but also some, and maybe. There are a lot of vaccines that mimic just the spike (or part of it) directly. The antibodies they trigger may not help at all against a non-spike, different-spike variant. Some of the vaccines though are based on whole de-activated virus for example, so they may still work. In other words all the trial efficacy results will become invalid, but the vaccines may not all stop working.
In any case there's a question of when does a mutation develop new behaviours - become more/less infectious, quicker/slower incubation time, and how damaging will it be. The SARS2 S protein may be part of the perfect storm that has made SARS2 so dangerous.
For sure though, the whole development push this time round will be a massive boost to the next round of vaccine development whether that's a changed spike Sars2 or a completely new virus. The teams doing this around the world will have learned an immense amount about processes, techniques and some of the novel technologies.